<- Go home

Added to YB: 2025-09-10

Pitch date: 2025-09-08

CPH.TO [neutral]

Cipher Pharmaceuticals Inc.

+14.07%

current return

Author Info

Raging Bull Investments is a lawyer by background who shares actionable investment ideas on value opportunities with a catalyst. Sign up for the newsletter.

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 330.8M

Pitch Price

CAD 16.77

Price Target

46.00 (+140%)

Dividend

N/A

EV/EBITDA

13.65

P/E

12.45

EV/Sales

6.52

Sector

Pharmaceuticals

Category

growth

Show full summary:
Raging Bull Investments | Idea Update - 9/8/2025 - Cipher Pharmaceuticals Inc.

CPH.TO (update): Epuris dominates 50%+ Canadian isotretinoin market w/ no patent risk; Natroba beats expectations w/ high-80s gross margins, potential DTC expansion; international opportunity mispriced at zero due to Trump MFN concerns; Absorica in-housing potential 2026; strong M&A platform w/ steady buybacks. Billion dollar co potential. TSR 180%, IRR 94%.

Read full article (2 min)